These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30679688)

  • 1. Development of Highly Sensitive Biosensors of RAF Dimerization in Cells.
    Miyamoto K; Sawa M
    Sci Rep; 2019 Jan; 9(1):636. PubMed ID: 30679688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.
    Grasso M; Estrada MA; Berrios KN; Winkler JD; Marmorstein R
    J Med Chem; 2018 Jun; 61(11):5034-5046. PubMed ID: 29727562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV; Hövermann D; Müller A; Wagner HJ; Weber W; Radziwill G
    Sci Rep; 2016 Mar; 6():23713. PubMed ID: 27025703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function.
    Bromberger S; Zadorozhna Y; Ressler JM; Holzner S; Nawrocki A; Zila N; Springer A; Røssel Larsen M; Schossleitner K
    Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38839106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies.
    Mayrhofer JE; Enzler F; Feichtner A; Röck R; Fleischmann J; Raffeiner A; Tschaikner P; Ogris E; Huber RG; Hartl M; Schneider R; Troppmair J; Torres-Quesada O; Stefan E
    Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31105-31113. PubMed ID: 33229534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Walter L; Heinzerling L
    Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New RAF kinase inhibitors in cancer therapy.
    Martin-Liberal J; Larkin J
    Expert Opin Pharmacother; 2014 Jun; 15(9):1235-45. PubMed ID: 24766074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.
    Vido MJ; Le K; Hartsough EJ; Aplin AE
    Cell Rep; 2018 Nov; 25(6):1501-1510.e3. PubMed ID: 30404005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells.
    Bauer D; Werth F; Nguyen HA; Kiecker F; Eberle J
    Cell Death Dis; 2017 Feb; 8(2):e2594. PubMed ID: 28151482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAF kinase dimerization: implications for drug discovery and clinical outcomes.
    Brummer T; McInnes C
    Oncogene; 2020 May; 39(21):4155-4169. PubMed ID: 32269299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-Raf Inhibition in the Clinic: Present and Future.
    Fiskus W; Mitsiades N
    Annu Rev Med; 2016; 67():29-43. PubMed ID: 26768236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
    Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
    Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical oncogenesis: are all BRAF inhibitors equal?
    Menzies AM; Kefford RF; Long GV
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):611-5. PubMed ID: 23795808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.
    Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
    Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance mechanism of the oncogenic β3-αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.
    Niu Y; Zhang Y; Yao X
    Chem Biol Drug Des; 2019 Feb; 93(2):177-187. PubMed ID: 30225883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of a closed kinase conformation induces RAF dimerization.
    Cancer Discov; 2013 Jul; 3(7):715. PubMed ID: 23847340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.